Efficacy and safety of ritlecitinib (PF06651600) in patients with alopecia areata and at least 50% scalp hair loss: results from the international ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled study (NCT03732807)
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined